New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:09 EDTCCXIChemoCentryx announces Phase I clinical trial for CCX972 in France
ChemoCentryx announced the initiation of a Phase I clinical trial for CCX872, the company's next-generation of orally administered inhibitors targeting the chemokine receptor known as CCR2. The double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CCX872 in 40 healthy adult subjects. ChemoCentryx' CCR2 program also includes CCX140, the Company's lead CCR2 inhibitor, currently in Phase II clinical trials for the treatment of diabetic nephropathy.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
13:04 EDTCCXIOn The Fly: Midday Wrap
Subscribe for More Information
09:13 EDTCCXIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Adobe (ADBE), up 5.5% after reporting first quarter results and that it will acquire Fotolia for approximately $800 in cash. ALSO HIGHER: ChemoCentryx (CCXI), up 107.1% after Phase II clinical trial in diabetic nephropathy with CCX140 met its primary endpoint... Oncothyreon (ONTY), up 15.8% after announcing exclusive agreement with Array BioPharma (ARRY)... Talisman Energy (TLM), up 24.4% after a report that Repsol (REPYY) is preparing to make a C$6.00 per share bid... GoPro (GPRO), up 4.4% after being upgraded to Overweight from Neutral at JPMorgan. LOWER: Emerald Oil (EOX), down 18% after cutting fiscal 2015 guidance, naming new COO, and providing an updated fiscal 2015 development plan... Goodrich Petroleum (GDP), down 8.2% after being downgraded to Underweight from Overweight at JPMorgan... MEI Pharma (MEIP), down 3.9% after 10M share Secondary priced at $4.00... Heritage-Crystal Clean (HCCI), down 6.6% after 3.1M share Secondary priced at $10.00.
09:03 EDTCCXIChemoCentryx up 107.1% after Phase II trial met primary endpoint
Subscribe for More Information
06:46 EDTCCXIChemoCentryx to host conference call
Subscribe for More Information
06:38 EDTCCXIChemoCentryx reports Phase II nephropathy with CCX140 trial met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use